CPNE7

Across TCGA pan-cancer cohorts, CPNE7 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated CPNE7 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CPNE7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPNE7 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

THYM, LUAD, and LUSC are the cancer types where CPNE7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
LUAD	OS	Median	II,III,IV	0.053	0.751	<.001	30	view →
LUSC	OS	Median	II,III,IV	0.253	0.747	<.001	24	view →
GBM	OS	Median	All	0.005	0.416	<.001	12	view →
LIHC	OS	Median	All	0.031	0.777	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
STAD	DFS	Median	All	1.000	0.647	.027	4	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	II,III,IV	1.000	0.307	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

CPNE7–THYM (OS)

Open the THYM breakdown →